Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.52 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | PAM | P19021 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31036510 | 1.00 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL31399579 | 1.00 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL19032585 | 1.00 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL19032459 | 1.00 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL31399531 | 1.00 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL18641884 | 1.00 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL21425737 | 0.94 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL21828429 | 0.94 | DGKA (0.61) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL10392579 | 0.94 | DGKA (0.69) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL22746298 | 0.94 | DGKA (0.69) | DGKAPRSS1PRSS2PRSS3NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739652-A1 | LIPIDS AND COMPOSITIONS THEREOF | Kernal Biologics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4562021-A2 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON | AldexChem Kft. (HU) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025008006-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 中生复诺健生物科技(上海)有限公司 | 2025-01-09 | — | — | WO | disclosed |
| WO-2025010290-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| WO-2024023174-A2 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON | ALDEXCHEM KFT. (HU) | 2024-02-01 | — | — | WO | disclosed |
| CN-117069785-A | Lipid compounds and lipid nanoparticle compositions | 中生复诺健生物科技(上海)有限公司 | 2023-11-17 | — | — | CN | disclosed |
| EP-4262819-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | Beam Therapeutics Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| CN-116887841-A | Nanomaterials comprising ester-linked acetals | 比姆医疗股份有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230242474-A1 | LIPID COMPOUND AND THE COMPOSITION THEREOF | GUANGZHOU RIBOBIO CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| WO-2023133946-A1 | CATIONIC LIPID COMPOUND, COMPOSITION CONTAINING SAME AND USE THEREOF | 杭州天龙药业有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-20230202966-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
| CN-115286674-A | Cationic liposome and preparation method thereof | 湖北英纳氏生物科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-114874104-A | Preparation method of cationic liposome SM-102 and analogues thereof | 湖北英纳氏生物科技有限公司 | 2022-08-09 | — | — | CN | disclosed |
| WO-2022140252-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140252-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331657-A1 | NANOMATERIALS COMPRISING ESTER-LINKED ACETALS | LIPA, SGMS1, SGMS2 | DGKA 190/4885PRSS1 4236/4885PRSS2 4514/4885 |
| US-20230242474-A1 | LIPID COMPOUND AND THE COMPOSITION THEREOF | NPC1L1, NPC1, SGMS1 | DGKA 1716/4885PRSS1 3287/4885PRSS2 3913/4885 |
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | LIPC, LIPA, NPC1L1 | DGKA 704/4885PRSS1 3821/4885PRSS2 4069/4885 |
| US-20230202966-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, ABHD16A | DGKA 320/4885PRSS1 1485/4885PRSS2 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.